Young streak off a low base: a short run of consecutive-period improvement has just started, after a stretch that gave i
The model's full reasoning — Q4 2022 call → NOWe need answer YES or NO based on transcript. Need determine if management conveys a young run of consecutive periods of improvement in a part business that had been unimpressive, causes attached to company and still in force. Let's analyze transcript. Management discusses Q4 2022 results. Revenue declined 10% y/y. But there are bright spots. Specifically: "Excluding ReNu, NuCel and Dermagraft, our team delivered low double-digit growth in the number of accounts that we serve in both the hospital outpatient setting and the physician office setting compared to the prior period. We delivered double-digit growth in sales of Advanced Wound Care products in the hospital outpatient setting, which partially offset the impact of the headwinds that we saw in the office setting. And we’re pleased by the encouraging market response to our new product introductions." Also they mention new product introductions and growth in accounts. However, overall sales declined. Need identify a part of business with young run of consecutive periods improvement. Management says "non-PuraPly products" expected to grow 28% in 2023. But that's guidance. Did they describe sequential improvement? They mention "We have more active accounts. We have more units being sold both in the outpatient setting and in the physician office." But not necessarily consecutive quarters. Also "our trends in 2023 so far are encouraging" but 2023 not reported. Question: "On this call, does management convey that the business has NOW PUT TOGETHER A SHORT, STILL-YOUNG RUN OF CONSECUTIVE PERIODS OF REAL IMPROVEMENT — roughly two to four periods in a row of getting better — in a part of the business that, until recently, had been giving investors little reason to expect it, AND that the causes of this young run are attached to the company itself and still in force?" Need see if management frames recent periods as sequential improvement. They report Q4 2022 results. They compare to Q4 2021. There is no mention of Q3 vs Q4 improvement. They mention "As a result of strong momentum in patient enrollment towards the end of the year, we enrolled more than 500 patients in this Phase 3 clinical study." That is clinical trial enrollment, not business improvement. Could be "progress" in ReNu trial. But question is about part of business. Also "We have more active accounts.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OLPX | Olaplex Holdings, Inc. | Q4 2023 | 2024-02-29 | D |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LEG | Leggett & Platt, Incorporated | Q3 2021 | 2021-11-02 | C |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
WRBY · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
ASB · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
KOPN · Q4 2023 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...